GSK New Product Launches In 2004 Will Include Vesicare, Avandaryl
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline expects that Vesicare and Avandaryl will be approved before the end of the year, the company said Sept. 14 at the Bear Stearns health care conference in New York
You may also be interested in...
Takeda Files Actos/Metformin Combination Actoplus Met For Type 2 Diabetes
NDA submission of pioglitazone/metformin combo marks beginning of Takeda’s expansion in the U.S. diabetes market; the firm has insulin resistance-improving agents in Phase II and Phase III.
Takeda Files Actos/Metformin Combination Actoplus Met For Type 2 Diabetes
NDA submission of pioglitazone/metformin combo marks beginning of Takeda’s expansion in the U.S. diabetes market; the firm has insulin resistance-improving agents in Phase II and Phase III.
GSK Sweetens Early-Stage Diabetes Pipeline With HGS’ Albugon
The preclinical peptide hormone will likely be developed for Type-2 diabetes. Human Genome Sciences believes potential advantage with Albugon is prolonged half-life.